The pharmaceutical research and development (R&D) pipeline face a persistent and unsustainable productivity paradox. Characterized by escalating capitalized costs that approach 2. 6 billion per approved therapeutic, protracted development timelines of 10 to 15 years, and a clinical success rate below 8%, the traditional R&D model is under immense economic strain. 1 This comprehensive review analyzes how the convergence of six distinct technologies—Artificial Intelligence (AI) and Machine Learning (ML), CRISPR-Cas gene editing, High-Throughput Screening (HTS), Organ-on-a-Chip (OOC) micro physiological systems, Blockchain, and Quantum Computing (QC) —offers a synergistic framework to fundamentally re-engineer the drug discovery value chain. Our analysis, based on a synthesis of industry data, economic evaluations, and technical literature, quantifies the potential for significant, stage-specific improvements. These include up to a 40% reduction in discovery costs through AI-driven target identification, a 70% to 80% compression of screening timelines via HTS, a potential five-fold improvement in the preclinical-to-approval success rate attributable to the combined power of CRISPR-based validation and OOC-based preclinical testing, and a prospective 90% or greater reduction in molecular simulation times with the advent of quantum computing. 1 We conclude that the strategic and integrated adoption of these technologies represents not merely an incremental improvement but an essential paradigm shift. This shift moves the industry from a high-attrition, empirical process toward a predictive, efficient, and patient-centric model of pharmaceutical innovation, offering the most viable path to resolving the industry's core economic and scientific challenges.
G L Ray (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: